-
2023-505223-31-00
4
2019-06-14
Localized ER+ breast cancer
-
2023-510357-42-00
5
2019-05-22
hormone receptor (HR)-positive, HER2-negative,
early breast cancer (EB
-
2024-513396-41-00
5
2019-05-15
PATIENTS WITH NEW DIAGNOSIS MULTIPLE MYELOMA WITH AGE >= 65 YEARS OR N
-
2024-511781-37-00
4
2019-04-16
YOUNG PATIENTS AFFECTED BY MULTIPLE MYELOMA (MM) TO THE DIAGNOSIS ELIG
-
2022-502937-24-00
5
2019-01-02
Atopic Dermatitis
-
2023-506125-10-00
5
2018-12-24
Multiple Myeloma
-
2024-513912-89-00
10
2018-12-13
Primary Or Secondary (Post-PV MF or Post-ET-MF) Myelofibrosis (MF) Wit
-
2023-510517-26-00
9
2018-10-26
Acute Myeloid Leukemia
-
2023-506112-40-00
5
2018-09-26
R/R Multiple Myeloma
-
2024-512049-17-00
6
2018-09-05
Newly diagnosed MM patients >= 65 years old or ineligible for autologo
-
2023-503378-19-00
5
2018-08-23
Chronic Plaque Psoriasis
-
2023-509856-32-00
5
2018-07-15
acute lymphoblastic leukemia in children and adolescents
-
2024-513070-21-00
4
2018-02-15
Relapsed Acute Lymphoblastic Leukemia (ALL)
-
2024-514417-34-00
5
2017-12-14
Cancer
-
2024-515499-12-00
5
2017-10-02
Acute lymphoblastic leukemia
-
2024-515152-20-00
4
2023-03-02
Stage III and high-risk stage II resected colon cancer patients.
-
2024-514562-40-00
4
2025-03-13
Hidradenitis suppurativa (HS)
-
2023-508812-45-00
10
2024-11-11
Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures
-
2023-504964-41-00
7
2024-11-06
Idiopathic pulmonary fibrosis
-
2024-511360-87-00
5
2024-10-02
hidradenitis suppurativa (HS)
-
2023-509371-16-00
4
2024-09-25
Idiopathic Pulmonary Fibrosis
-
2023-508377-82-00
10
2024-06-27
Hidradenitis Suppurativa (HS)
-
2023-506558-20-00
5
2024-06-26
Dermatitis atopic
-
2023-504092-25-00
4
2024-06-04
Cystic Fibrosis